

Pressure BioSciences, Inc.

15:29 19 Dec 2019

Pressure BioSciences sees soaring consumables sales in third quarter, projects revenue growth in 2020

Pressure BioSciences Inc (OTCMKTS:PBIO) reported third quarter results before the bell Thursday that highlighted surging growth in consumable product and scientific services revenue.

The producer of pressure-based instruments saw sales of its pressure cycling technology (PCT) platform exceed \$100,000 in a quarter for the first time, a 158% increase — more than double — year over year.

"A significant portion of this accelerating growth came from scientists working in cancer research centers worldwide," CEO Richard Schumacher said in a statement. "These researchers use PBI's PCT platform in studies focused on improving cancer diagnostics, prognostics, therapeutics and prevention."

READ: Zachs: Pressure BioSciences at 'tipping point,' initiates coverage with \$4.44 target

For instance, he said, PBI announced in October that a cancer researcher at the Inova Women's Hospital in Virginia had developed a novel workflow that could identify biomarkers associated with cancer, a process of which the PCT platform was an essential part.

"Based on multiple recent publications and presentations by cancer research scientists that have highlighted the importance of our PCT platform in their work, we believe our PCT-based products (instruments and consumables) position us well to take advantage of this very large and growing market," Schumacher said. "Because of this, and because of feedback received from many cancer researchers, we believe our PCT-based products will show significant revenue increases in 2020."

Also in the quarter, PBI dove into the CBD market with the launch of its proprietary processing system, the BaroShear K45, which the company said revolutionizes the manufacturing of water-soluble CBD oil. In fact, PBI has already received three purchase orders for the BaroShear K45 system.

In addition, the company expanded its recently launched BaroFold contract services business by entering into a six-figure agreement with a multinational multi-billion-dollar biopharma company.


Overall, revenue for the three months ended September 30 fell 4% year over year, to \$501,200 from \$521,766. The reason for the slight dip was primarily due to a loss in grant revenue and a shift in resources to building up its commercial platform, the company said.

Similarly, the Massachusetts-based company's operating loss was \$1.07 million, up 15% year over year. In addition to the grant revenue, an increased use of investor relations services, non-cash stock compensation, and employee costs relating to a new chief commercial officer contributed to the shift.

Price: 1.45

Market Cap: \$5.18 m

1 Year Share Price Graph



October 2019 May 2020 October 2020

Share Information

Code: PBIO

Listing: OTCQB

52 week	High	Low
	4.49	0.6006

Sector: Medical technology & services

Website: www.pressurebiosciences.com

Company Synopsis:

Pressure BioSciences Inc. (OTCQB: PBIO): A leader in the sale of innovative, broadly enabling, pressure-based instruments and consumables for the worldwide life sciences industry.

action@proactiveinvestors.com

On a per share basis, the company saw a loss of \$2.20 compared to last year's loss of \$2.01 in the same period.

Pressure BioSciences stock climbed 2.1% to \$0.69 on Thursday.

—Updated to include stock movement—

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter [@andrew_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).